SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorization at Blue Cross Blue Shield of Michigan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Michigan requires GLP-1 Receptor Agonist prior-authorization documentation for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Michigan reviews SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior authorizations against its medical policy for GLP-1 Receptor Agonist. Blue Cross Blue Shield of Michigan-specific context: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Michigan's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Step therapy via OptumRx (PBM since 2024)
- Site-of-care reductions for infusions
- Behavioral health prior auth
- OON balance bill disputes
SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Weight-loss exclusion (Wegovy)
- Step therapy requiring oral semaglutide before injectable
- BMI threshold above FDA label
- Non-formulary tier 4 specialty
Sold as Ozempic (T2D), Wegovy (weight loss + CV risk reduction), Rybelsus (oral T2D). Wegovy received FDA CV indication March 2024 based on SELECT trial.
Manufacturer patient-assistance program: NovoCare — relevant when a Blue Cross Blue Shield of Michigan denial sticks and the patient needs bridge access while appealing.
How Blue Cross Blue Shield of Michigan approaches GLP-1 receptor agonists PAs
For SEMAGLUTIDE (WEGOVY), check whether the current Blue Cross Blue Shield of Michigan GLP-1 receptor agonists policy cites step therapy via optumrx (pbm since 2024). Pharmacy-benefit review for SEMAGLUTIDE (WEGOVY) at Blue Cross Blue Shield of Michigan is routed through OptumRx (switched from Express Scripts January 2024). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Blue Cross Blue Shield of Michigan; if denied, use the filing date and route printed on that denial notice. The current Blue Cross Blue Shield of Michigan policy may distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda); verify any benefit-exclusion language in the member product. Blue Cross Blue Shield of Michigan is domiciled in MI, so unresolved appeals escalate to the MI insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://providers.bcbsm.com) with the same packet plus an applicable, current clinical source supporting SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross Blue Shield of Michigan denial on DenialHelp.
Contact Blue Cross Blue Shield of Michigan
- Provider portal: https://providers.bcbsm.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Michigan need for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior auth?
Blue Cross Blue Shield of Michigan's typical PA packet for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For GLP-1 Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross Blue Shield of Michigan?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) at Blue Cross Blue Shield of Michigan?
Preparation scenarios to check against the current notice and policy include: Step therapy via OptumRx (PBM since 2024); Site-of-care reductions for infusions; Behavioral health prior auth. These are not measured frequency claims. For SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Why does Blue Cross Blue Shield of Michigan require specific BMI documentation for SEMAGLUTIDE (WEGOVY)?
Blue Cross Blue Shield of Michigan's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management SEMAGLUTIDE (WEGOVY) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. Verify current criteria and timing in the member-specific payer source. Pharmacy-benefit handling is routed through OptumRx (switched from Express Scripts January 2024). External-review escalation for Blue Cross Blue Shield of Michigan fully-insured policies sits with the MI insurance department.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Michigan on SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Michigan
- Aflibercept at Blue Cross Blue Shield of Michigan
- Apixaban at Blue Cross Blue Shield of Michigan
- Atezolizumab at Blue Cross Blue Shield of Michigan
- SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) at UnitedHealthcare
- SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) at Elevance Health
- SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) at Aetna
Generate the SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) PA packet
Open ApprovalHelp — generate a SEMAGLUTIDE (Wegovy, Ozempic, Rybelsus) prior-auth packet tailored to Blue Cross Blue Shield of Michigan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com